Le Lézard
Classified in: Ebola virus, Health
Subject: SVY

Global Human Vaccines Industry



NEW YORK, Nov. 15, 2018 /PRNewswire/ -- This report analyzes the worldwide markets for Human Vaccines in US$ Million by the following Product Segments: Pediatric Vaccines, and Adult Vaccines.



Read the full report: https://www.reportlinker.com/p05621724



The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.

Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

The report profiles 66 companies including many key and niche players such as:
- ALK Abelló A/S
- Altimmune, Inc.
- Astellas Pharma Inc.
- Bavarian Nordic
- BiondVax Pharmaceuticals Ltd.
- Bharat Biotech



Read the full report: https://www.reportlinker.com/p05621724

HUMAN VACCINES MCP-1
MARKET ANALYSIS, TRENDS, AND FORECASTS, OCTOBER 2
CONTENTS

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study


2. INDUSTRY OVERVIEW

Human Vaccines: A Prelude
Growing Incidence of Infectious Diseases Drives the Global Human Vaccines Market
Total Number of Infectious Disease Covered under Vaccination
Table 1: Global Total Number of Infectious Disease Reported Cases: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)
Table 2: Diphtheria: Total Number of Reported Cases by Geographic Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)
Table 3: Measles: Total Number of Reported Cases by Geographic Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)
Table 4: Mumps: Total Number of Reported Cases by Geographic Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)
Table 5: Pertussis: Total Number of Reported Cases by Geographic Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)
Table 6: Polio: Total Number of Reported Cases by Geographic Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)
Table 7: Rubella: Total Number of Reported Cases by Geographic Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)
Table 8: Rubella (CRS): Total Number of Reported Cases by Geographic Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)
Table 9: Tetanus (neonatal): Total Number of Reported Cases by Geographic Region: 1980, 1990, 2000, and 2013-2
(includes corresponding Graph/Chart)
Table 10: Tetanus (Total): Total Number of Reported Cases by Geographic Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)
Table 11: Yellow Fever: Total Number of Reported Cases by Geographic Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)
Conjugate Vaccines Rule in Human Vaccines Market
Pneumococcal Vaccines - A Major Segment
Vaccine Pipeline by Major Companies
GSK Vaccine Pipeline
Merck Vaccines Pipeline (As on Aug 2018)
Pfizer Vaccines Pipeline (As on July 31, 2018)
Sanofi Vaccines Portfolio (As on Q1 2018)
Emergent BioSolutions Inc. - Vaccine Pipeline
Astellas Pharma - Vaccines
Pediatric Vaccines Dominate the Human Vaccines Market
Select Pediatric Vaccines
Adults Vaccine Market to Witness Rapid Growth, Driven by Government Initiatives
Select Adult Vaccines
Developed Markets Dominate, Emerging Regions to Exhibit the Fastest Growth
Pneumococcal Vaccines Market Set to Witness Rapid Growth
Influenza Vaccines Market: A High Growth Segment
Cancer Vaccines Market Offers Potential Opportunities
Customized Tumor-Specific Cancer Vaccines Catching On
Competitive Scenario
Table 12: Global Human Vaccines Market by Leading Player (2017): Annual Sales in US$ Million and Market Share for GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, CSL, Mitsubishi Tanabe, and Others (includes corresponding Graph/Chart)
Table 13: Select Leading Human Vaccines Worldwide, by Sales Value: 2017 (In US$ Million)
Vaccine Pricing: A Review
Table 14: Expanded Program of Immunization Vaccine Prices for Year 2018


3. SEGMENT OVERVIEW, GROWTH DRIVERS AND MARKET TRENDS

Combination Vaccines Market Driven by Fast Expanding Pediatric Population
List of Combination Vaccines in the US: 2018
Gardasil 9 Offers Protection against HPV for Expanded Age Group
Increasing Demand for Recombinant Vaccines
Global Cholera Vaccines Market
Further Clinical Trials Needed for an Effective Zika Vaccine
Merck's rVSV-ZEBOV Ebola Vaccine used for Ring Vaccination in Congo
Rising Dengue Cases Drive Vaccines Demand
Sanofi's Dengue Vaccine First-to-Market
Dengue Vaccine Pipeline
EMA Recommends Approval of Dengue Vaccine
Vaccine for AIDS
Staggering Global Statistics of AIDS - Opportunity Indicator
Table 15: HIV Infection Statistics Worldwide: As of 2
(includes corresponding Graph/Chart)
Table 16: People living with HIV by WHO Region: 2
(includes corresponding Graph/Chart)
Table 17: New HIV Infections by Region: 2017
Table 18: Worldwide HIV-related Deaths by Geographic Region: 2016-2017 (includes corresponding Graph/Chart)
Toxoid Vaccines Market
H1N1 Vaccines Market
HSV Vaccine on the Horizon
HSV Vaccines Currently in Clinical Trials
Rising Disease Incidence and Increasing Awareness Drive the Global Meningococcal Vaccines Market
BCG Vaccines
Key TB Vaccine Candidates in the Pipeline: 2018
New Vaccine for Herpes Zoster or Shingles
Two-dose Hepatitis B Vaccine for Adults
Global Rotavirus Vaccines Market
Typhoid Vaccines Market
Measles Vaccines Market
DNA Vaccines: Engineering Growth
Mobile Money Encourages Parents for Vaccinating Children
Noninjectable Vaccines: Gain without Pain
Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines
Novel Technologies Ensure Timely Vaccine Delivery for Patients in Remote Locations
Smart mRNA Vaccines
Growing Pricing Pressure - A Major Market Deterrent
Safety Issues Come to the Fore
Novel Vaccination Guidelines Mitigate Risks Associated with Developing Shoulder Injuries
BioWarfare: Threat Perception and Preparedness
Overview of Potential Bio-Terrorist Agents
Smallpox (Variola Major)
Anthrax (Bacillus Anthracis)
Plague (Yersinia Pestis)
Botulism (Clostridium Botulinum)
Tularemia (Francisella Tularensis)
Tackling Cold Chain Issues
Trade Statistics
Table 19: Global Exports of Human Vaccines by Leading Country (2015, 2016 & 2017): Percentage Share Breakdown of Export Value for Leading Exporters (includes corresponding Graph/Chart)
Table 20: Global Imports of Human Vaccines by Leading Country (2015, 2016 & 2017): Percentage Share Breakdown of Import Value for Leading Importers (includes corresponding Graph/Chart)


4. PRODUCT OVERVIEW

Introduction to the Concept of Immunity
Role of Vaccines in Strengthening the Immune System
Vaccines and Immunotherapy
Historical Overview of Vaccines
How it Began
So Far So Good
Successful Vaccine Introductions in the Past
Contribution of Animal Research to Vaccine Production
Types of Vaccines
Live, Attenuated Vaccines
Combination Vaccines
Killed or Inactivated Vaccines
DNA & Recombinant DNA Vaccines
Toxoids
Cellular Fractions
Conjugate Vaccines
Subunit Vaccines
Passive Immunization
Prophylactic Vaccines
Prevention Better than Cure
Prophylactic Pediatric Vaccines
Vaccination over the Years
BCG Vaccine
Growth Boosting Factors for TB Vaccines
Demand Restraining Factors for TB Vaccines
Major Issues to be addressed in the TB Vaccine Market
Hemophilus Influenza Type B Vaccine
Diphtheria/Tetanus/Pertussis Vaccines
Hepatitis A Vaccine
Hepatitis B Vaccine
Hepatitis B Epidemiology
Measles/Mumps/Rubella Vaccines
Rotavirus Vaccines
Polio Vaccines
Varicella Vaccine
Combination Vaccines
Prophylactic Adult Vaccines
Hepatitis A Vaccine
Hepatitis B Vaccines
Key Issues Affecting the Adult Hepatitis Vaccines Market
Cholera Vaccine
Japanese Encephalitis Vaccines
Influenza Vaccines
Influenza A Virus
Influenza A (H1N1) Virus
Lyme Disease Vaccine
Pneumococcal Disease Vaccines
Meningococcal Vaccines
Rabies Vaccines
Typhoid Vaccine
Yellow Fever Vaccine
Mechanisms for Vaccine Delivery
Edible Vaccines
Oral Vaccines
Tablet Based Vaccines
Mucosal Delivery
Transdermal Patch Delivery
Storage Problems
Perfluorocarbons as Alternative to Overcome Storage Problems
Costs
Standards for Vaccine Safety and Quality


5. COMPETITIVE LANDSCAPE


5.1 Focus on Select Players
ALK - Abelló A/S (Denmark)
Altimmune, Inc. (USA)
Astellas Pharma Inc. (Tokyo)
Bavarian Nordic (Denmark)
BiondVax Pharmaceuticals Ltd. (Israel)
Bharat Biotech (India)
GlaxoSmithKline Plc. (UK)
Hualan Biological Engineering Inc. (China)
Janssen Pharmaceuticals, Inc. (USA)
MedImmune (USA)
Merck Sharp & Dohme Corp., (USA)
Mitsubishi Tanabe Pharma Corporate (Japan)
Pfizer, Inc. (USA)
Sanofi Pasteur SA (France)
Serum Institute of India Pvt. Ltd. (India)
Seqirus (UK)
SK BioScience (Korea)
Takeda Pharmaceutical Company Limited (Japan)
Zydus Cadila (India)
5.2 Clinical Trials in the Vaccines Market
NIH Initiates Clinical Trial for Zika Virus Vaccine Candidate
Bavarian Nordic Publishes Positive Data for Universal RSV Vaccine from Phase 2 Extension Study
PaxVax Initiates Phase 2b Trial for Chikungunya Vaccine
Merck Plans to Initiate Studies for PCV-15 (V114)
BiondVax Initiates Phase 2 Clinical Trial of its Universal Flu Vaccine
Bavarian Nordic Announces Positive Results for Imvamune® Smallpox Vaccine
Johnson & Johnson and Partners Plan to Initiate Efficacy Study for Investigational Mosaic HIV-1 Preventive Vaccine
Takeda Launches Phase 1 Clinical Trial for Zika Vaccine Candidate
Bavarian Nordic Secures Contract from the U.S. Government to Supply Freeze-Dried Imvamune Smallpox Vaccine
Bavarian Nordic Announces Positive Data for a Universal RSV Vaccine from Ongoing Phase 2 Study
Johnson & Johnson Announces Positive Clinical Data for Investigational HIV Preventive Vaccine
BiondVax Announces Positive Results from Phase 2b Clinical Trial for its Universal Flu Vaccine
CHMP Issues Positive Opinion for GSK's Synflorix Pneumococcal Vaccine
GSK Announces Positive Results for Shingles Vaccine Shingrix from Phase III Revaccination Study
Pfizer Initiates Phase 1 Clinical Trial for Investigational Group B Streptococcus Vaccine
Inovio and GeneOne to Initiate Phase 1 Human Trial for Zika DNA Vaccine
Takeda Begins Phase2b Trial for World's First Norovirus Vaccine
Bavarian Nordic Announces Positive Results from Phase 1 Trial of RSV Vaccine
Investigational Vaccine for P.vivax Malaria Enters Human Trials
5.3 Product Launches/Approvals
SK Chemicals Introduces Shingles Vaccine SKYZoster
Serum Institute of India Introduces Novel Vaccines - Rotasiil & Rabishield
Inovio Announces Positive Results from Phase 1 Trial for Zika Vaccine
PharmaJet® in Partnership with Serum Institute Launches Needle-Free MMR Vaccine
Cipla Introduces Hepatitis B Vaccine in India
FDA Approves 2016/17 Formulation of Protein Sciences Corporation's Flublok
Sanofi's Dengue Vaccine Approved in Costa Rica
GSK Supplies Flu Vaccines based on Valneva's EB66 Cell Line
FDA Approves Seqirus' FLUCELVAX QUADRIVALENTtm Influenza Vaccine
China Launches HFMD Vaccine
Bharat Biotech Introduces ZIKAVAC® Vaccine for Zika Infection
Sanofi Pasteur Launches Vaccine R&D Project for Zika Virus Infection
5.4 Recent Industry Activity
FDA Approves HPV Vaccine Usage for Adults Aged around 27 to 45
BiondVax Relocates to New Universal Flu Vaccine Manufacturing Facility
SK Chemicals Plans to Dominate Shingles Vaccine Market, with the Launch of SKYZoster
European Agency Proposes Approval of Sanofi's Dengvaxia to Prevent Dengue
CEPI Collaborates with Partners to Launch Lassa Vaccine
Emergent BioSolutions Acquires Cholera and Typhoid Vaccines
SK Chemicals Receives Marketing Authorization for Chickenpox Vaccine, Sky Varicella Injection
SK Chemicals Partners with Daewoong Pharmaceutical to Market and Sell Herpes Zoster Vaccine
Skchemicals Spins off Vaccine Division
Sanofi Invests in Canadian Vaccine Facility
GSK Receives European Approval for Fluarix Tetra
GSK Receives Breakthrough Therapy Designation for meningitis B vaccine Bexsero
Seqirus Joins UIVI to Advance Universal Flu Vaccine Research
Bharat Biotech Receives Prequalification for Rotavirus Vaccine, ROTAVAC® from WHO
WHO Grants Prequalification for Bharat Biotech's Typbar TCV®
BiondVax Receives Patent for the Universal Flu Vaccine
Altimmune Merges with PharmAthene
Aviragen Therapeutics and Vaxart Enters into a Merger Agreement
BiondVax Signs an Agreement with NIH to Conduct Phase 2 trial in the U.S. for Universal Flu Vaccine
Vedantra Pharmaceuticals Collaborates with Neon Therapeutics to Develop Novel Cancer Immunotherapies
GSK Receives Approval for Shingrix in Canada
Sanofi Plans to Inaugurate New Vaccine Production Facility in France
SK Chemicals Receives Marketing Authorization for SKYZoster
Bavarian Receives Procurement Contract for the Freeze-dried IMVAMUNE® Smallpox Vaccine from BARDA
Bavarian Nordic Agrees with Janssen to Develop Vaccine against Hepatitis B virus (HBV) and the Human Immunodeficiency Virus (HIV-1)
Seqirus Invests in New Influenza Vaccine Production Facility
BiondVax Agrees to Lease Mid-Size Commercial Facility to Manufacture Universal Flu Vaccine
Takeda and Biological E. Limited Announces Partnership to Develop Low-Cost Combination Vaccines
PaxVax and TerahVax Signs an Agreement to Market and Distribute PaxVax specialty vaccine in South Korea
PPD Announces the Expansion of Vaccine Development Laboratory
SK Chemicals and PATH Signs an Agreement to Develop New Rotavirus Vaccine
Seqirus Announces Major Advancement in Cell-Based Influenza Vaccine Technology
PaxVax Initiates a Clinical Trial to Modernized Adenovirus Vaccine
BARDA Funds Altimmune for Developing First-In-Class Anthrax Vaccine Candidate, NasoShieldtm
PaxVax Announces Partnership with NIH and DoD to Develop a New chikungunya Vaccine Program
Sanofi Pasteur and MSD Announces the End of Joint Vaccines Business in Europe
WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer's Prevnar 13
Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha Biotechnics' Facility
Bavarian Nordic Announces IMVAMUNE Supply Contract with US Government
Stellar Biotechnologies and Neovacs Form JV to Develop Conjugated Vaccines
WHO Recommends Sanofi's Dengvaxia in Nations with Widespread Dengue
Kaketsuken to Sell Vaccines Business to Astellas
Sanofi and Merck End Joint Venture on Vaccines
GeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever Vaccine
Bavarian Nordic Collaborates with Evaxion for Vaccine against MRSA


6. GLOBAL MARKET PERSPECTIVE

Table 21: World Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 22: World Historic Review for Human Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 23: World 14-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2011, 2
and 2024 (includes corresponding Graph/Chart)
Table 24: World Recent Past, Current & Future Analysis for Pediatric Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 25: World Historic Review for Pediatric Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 26: World 14-Year Perspective for Pediatric Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2011, 2
and 2024 (includes corresponding Graph/Chart)
Table 27: World Recent Past, Current & Future Analysis for Adult Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 28: World Historic Review for Adult Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 29: World 14-Year Perspective for Adult Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2011, 2
and 2024 (includes corresponding Graph/Chart)


7. REGIONAL MARKET PERSPECTIVE


7.1 The United States
A.Market Analysis
Table 30: Reported Cases and Deaths from Vaccine Preventable Diseases, United States (2010-2016)
Table 31: Reported Cases and Deaths from Vaccine Preventable Diseases, United States (2010-2016)
Pediatric Vaccines Market
Growth Drivers for US Pediatric Vaccines Market
Demand Restraining Factors for US Pediatric Vaccines Market
Commonly Administered Pediatric Vaccines
Table 32: Number of Vaccine Doses Distributed in the US: 2006-2016
Immunization Schedule for 2018
Influenza Activity and Prevention
Vaccines for Influenza Season 2018/19
List of Influenza Vaccines: For the Influenza Season 2018/19
Quadrivalent Live Attenuated Influenza Vaccine (LAIV4)
Table 33: CDC Price List for Pediatric Influenza Vaccines: 2018-2019
Table 34: CDC Price List for Adult Influenza Vaccines: 2018-2019
Product Billing Codes (CPT and Medicare) for Influenza Vaccines included for 2018/19 Season
Rise in Hepatitis A and Mumps Incidence Drives Advanced Immunization Techniques
Need for Immunization Schedule for Adults
Vaccines and Intended User Group
Vaccines Trade
Table 35: The US Exports of Human Vaccines by Country (2
and 2016) - Percentage Breakdown of Export Value for Leading Destinations (includes corresponding Graph/Chart)
Table 36: The US Imports of Human Vaccines by Country (2
and 2016): Percentage Breakdown of Import Value for Leading Countries of Origin (includes corresponding Graph/Chart)
B.Market Analytics
Table 37: The US Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2
(includes corresponding Graph/Chart)
Table 38: The US Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 39: The US 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
7.2 Canada
A.Market Analysis
Trade Statistics
Table 40: Canadian Imports of Human Vaccines by Country (2017 and 2016): Percentage Breakdown of Import Value for Leading Countries of Origin (includes corresponding Graph/Chart)
B.Market Analytics
Table 41: Canadian Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 42: Canadian Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 43: Canadian 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
7.3 Japan
A.Market Analysis
Controversy, Confusion and Hasty Actions Marr HPV Vaccination Market
B.Market Analytics
Table 44: Japanese Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 45: Japanese Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 46: Japanese 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
7.4 Europe
A.Market Analysis
Table 47: Number of Reported Cases of Select Infectious Diseases in the European Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)
Regulatory Mechanism for Vaccines in Europe
An Insight into European Influenza Vaccination Scenario
Cell-based Vaccine Production Remains Nascent, Egg-based widely used
EU Welcomes Quadrivalent LAIVs
B.Market Analytics
Table 48: European Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 49: European Historic Review for Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2
through 2024 (includes corresponding Graph/Chart)
Table 50: European 14-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
Table 51: European Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 52: European Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 53: European 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
7.4.1 France
Market Analysis
Table 54: French Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2
(includes corresponding Graph/Chart)
Table 55: French Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 56: French 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
7.4.2 Germany
Market Analysis
Table 57: German Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2
(includes corresponding Graph/Chart)
Table 58: German Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 59: German 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
7.4.3 Italy
Market Analysis
Table 60: Italian Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2
(includes corresponding Graph/Chart)
Table 61: Italian Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 62: Italian 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
7.4.4 The United Kingdom
Market Analysis
Table 63: The UK Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2
(includes corresponding Graph/Chart)
Table 64: The UK Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 65: The UK 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
7.4.5 Spain
Market Analysis
Table 66: Spanish Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2
(includes corresponding Graph/Chart)
Table 67: Spanish Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 68: Spanish 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
7.4.6 Russia
Market Analysis
Table 69: Russian Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2
(includes corresponding Graph/Chart)
Table 70: Russian Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 71: Russian 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
7.4.7 Rest of Europe
Market Analysis
Table 72: Rest of Europe Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2
through 2024 (includes corresponding Graph/Chart)
Table 73: Rest of Europe Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 74: Rest of Europe 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
7.5 Asia-Pacific
A.Market Analysis
Table 75: Number of Reported Cases of Select Infectious Diseases in South-East Asia Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)
Table 76: Number of Reported Cases of Select Infectious Diseases in Western Pacific Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)
Asian Vaccine Industry
Challenges
B.Market Analytics
Table 77: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 78: Asia-Pacific Historic Review for Human Vaccines by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2
(includes corresponding Graph/Chart)
Table 79: Asia-Pacific 14-Year Perspective for Human Vaccines by Geographic Region/Country - Percentage Breakdown of Dollar Sales for China, India, and Rest of Asia-Pacific Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
Table 80: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2
through 2024 (includes corresponding Graph/Chart)
Table 81: Asia-Pacific Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 82: Asia-Pacific 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
7.5.1 China
A.Market Analysis
Large Population Offers High Potential
Growth Drivers
China - A Lucrative yet Difficult to Permeate Market
B.Market Analytics
Table 83: Chinese Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2
(includes corresponding Graph/Chart)
Table 84: Chinese Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 85: Chinese 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
7.5.2 India
A.Market Analysis
Market Overview
Hepatitis B Vaccine in India
Combination Vaccines
The Patent Act (Third Amendment), 2005
B.Market Analytics
Table 86: Indian Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2
(includes corresponding Graph/Chart)
Table 87: Indian Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 88: Indian 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
7.5.3 Rest of Asia-Pacific
Market Analysis
Table 89: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2
through 2024 (includes corresponding Graph/Chart)
Table 90: Rest of Asia-Pacific Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 91: Rest of Asia-Pacific 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
7.6 Latin America
Market Analysis
Table 92: Latin American Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region/Country - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 93: Latin American Historic Review for Human Vaccines by Geographic Region/Country - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 94: Latin American 14-Year Perspective for Human Vaccines by Geographic Region/Country - Percentage Breakdown of Dollar Sales for Brazil, and Rest of Latin America Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
Table 95: Latin American Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2
through 2024 (includes corresponding Graph/Chart)
Table 96: Latin American Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 97: Latin American 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
7.6.1 Brazil
Market Analysis
Table 98: Brazilian Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 99: Brazilian Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 100: Brazilian 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
7.6.2 Rest of Latin America
Market Analysis
Table 101: Rest of Latin American Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 102: Rest of Latin American Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 103: Rest of Latin American 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
7.7 Rest of World
A.Market Analysis
Table 104: Number of Reported Cases of Select Infectious Diseases in Eastern Mediterranean Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)
Table 105: Number of Reported Cases of Select Infectious Diseases in African Region: 1980, 1990, 2000, and 2013-2
(includes corresponding Graph/Chart)
Nigeria: A Severely Underserved Market
B.Market Analytics
Table 106: Rest of World Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2
through 2024 (includes corresponding Graph/Chart)
Table 107: Rest of World Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 108: Rest of World 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)


8. COMPANY PROFILES


Total Companies Profiled: 66 (including Divisions/Subsidiaries - 76) The United States (25) Japan (6) Europe (15) - France (3) - Germany (2) - The United Kingdom (2) - Spain (1) - Rest of Europe (7) Asia-Pacific (Excluding Japan) (28) Middle East (1) Latin America (1)
Read the full report: https://www.reportlinker.com/p05621724

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 03:07
Cantargia AB (publ) today announce that new preclinical data on the antibody CAN04 (nidanilimab) will be presented at the scientific conference Antibody Engineering and Therapeutics in San Diego Dec 9-13, 2018. CAN04 is in clinical development for...

at 03:00
CHARLOTTE, N.C., Dec. 10, 2018 /PRNewswire-PRWeb/ -- The contribution limits of an HSA are likely one of the few barriers for investors putting more money aside?but with those contribution limits increasing, it is important that Self-Directed HSA...

at 03:00
SAN DIEGO, Calif., Dec. 10, 2018 /PRNewswire-PRWeb/ -- Nanomedical Diagnostics, leading producer of graphene biosensors for pharmaceutical and biotherapeutics research, announces a headquarters relocation to 9640 Towne Centre Drive, Suite 100,...

at 03:00
WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations, announces the expansion of its facilities in San Diego, California. WuXi AppTec's newly expanded facility...

at 03:00
Fever and pain in children can lead to lost or disrupted sleep, anxiety among the family and days of nursery, school or work missed due to illness1   Peak level flu season occurs between December and March each year2  New research has highlighted...

at 03:00
Biohaven Pharmaceutical Holding Company Ltd. today announced initial positive results from its ongoing long-term, open-label safety study of its oral calcitonin gene-related peptide (CGRP) receptor antagonist, rimegepant, for the acute treatment of...




News published on 15 november 2018 at 13:20 and distributed by: